Adamed moves to sue Novartis over unfair competition

Pharmaceutical company Adamed has declared that it will sue Novartis for employing unfair competition strategies. The controversy concerns Zafiron, a drug produced by Adamed, which is similar, if not the same as Novartis's Foradil. "Novartis complained to the Chief Pharmaceutical Inspector (GIF) who prohibited our advertising of the drug and then Novartis sent misleading information to doctors and pharmacists declaring that we do not have the required registrations," said Sławomir Mirek, president of Adamed. On Monday, after consulting analysts, GIF withdrew the ban. Now Adamed is demanding that Novartis send out fresh information to doctors, this time the truth. The drug produced by Adamed costs zł.3.2, while its Novartis equivalent about zł.31. (Puls Biznesu, p 10) A.F.